Weight Loss Drugs

Business

Northland Cuts Bitdeer Price Target to $25 After December Update, Maintains Bullish Stance

Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.

Jan 30, 2026

Business

Guggenheim Backs AtaiBeckley with Buy Rating, $11 Target, Citing Breakthrough Potential in Mental Health

Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.

Jan 30, 2026

Business

Morgan Stanley Downgrades Gogo Outlook as 5G Rollout Meets Industry Uncertainty

Analysts remain divided on Gogo Inc.'s trajectory as the in-flight connectivity provider navigates its 5G network launch against a backdrop of strategic shifts and evolving satellite technology debates.

Jan 30, 2026

Business

Century Therapeutics Gains Analyst Confidence with Extended Cash Runway and Key IND Submission on Horizon

Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.

Jan 30, 2026

Business

Citi Boosts Lexicon Pharmaceuticals Outlook on Novo Nordisk Partnership Progress

Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.

Jan 30, 2026

Business

Reed Jobs Launches $200M+ Venture Fund Aiming to Turn Cancer into a Manageable Condition

Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.

Jan 30, 2026

Business

Standex Delivers Strong Q2 Growth, Fueled by Grid and New Products; Reiterates FY2026 Outlook

Standex International reports robust second-quarter results, with organic growth reaching 6.4% and record quarterly orders. The company's strategic pivot towards high-growth markets like electrical grid infrastructure and new product development is now materially boosting the top line.

Jan 30, 2026

Business

Standex Surpasses Expectations in Q1 2026, Raises Full-Year Outlook on Strong Grid and New Product Momentum

Standex International reports a robust start to fiscal 2026, with sales climbing 27.6% and a record order book prompting an upward revision of its annual revenue forecast. The company's strategic pivot towards grid modernization and data center markets, highlighted by the rebranded 'Standex Electronics Grid' unit, fuels confidence in exceeding long-term targets.

Jan 30, 2026

Business

Amazon Announces 16,000 Job Cuts: A Strategic Pivot or Sign of Strain?

Amazon is set to eliminate 16,000 corporate roles, marking its largest workforce reduction since 2023. As the tech giant streamlines operations and doubles down on AI, investors are weighing the long-term strategy against near-term turbulence.

Jan 30, 2026

Business

OpenAI's Reported 2026 IPO: A High-Stakes Test for the AI Investment Frenzy

Sources indicate OpenAI is accelerating plans for a late-2026 public listing, a move that would place its massive cash burn and long road to profitability under intense investor scrutiny, potentially defining the next phase of the AI boom.

Jan 30, 2026

World

Newly Released Epstein Documents Contain Unverified Claims About Bill Gates and Other High-Profile Figures

A trove of documents released by the U.S. Department of Justice includes emails from Jeffrey Epstein making lurid, unsubstantiated allegations about Bill Gates, while also detailing his interactions with other prominent individuals.

Jan 30, 2026

Business

Oshkosh Navigates Tariff Headwinds and Mixed Demand to Set 2026 Course

Oshkosh Corporation topped revenue expectations in its latest quarter, but profit fell short as tariffs and cost pressures squeezed margins. The specialty vehicle maker's 2026 outlook balances targeted growth in some segments against persistent challenges in construction markets.

Jan 30, 2026

Business

Three Mid-Cap Stocks Facing Headwinds: Why Analysts Are Sounding the Alarm

While mid-cap companies often represent a sweet spot between growth and stability, heightened competition and shifting market dynamics are putting pressure on some notable names. Here’s a closer look at three stocks where caution may be warranted.

Jan 30, 2026

Business

iRhythm Holdings Gains Wall Street Favor as Cardiac Monitoring Demand Surges

Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.

Jan 30, 2026

Business

DexCom's Strong Q4 Preliminary Results and Ambitious 2026 Outlook Fuel Investor Optimism

DexCom Inc. (DXCM) has released preliminary Q4 figures that exceeded expectations and provided robust long-term guidance, reinforcing its position as a favored pick among analysts and hedge funds in the medical devices sector.

Jan 30, 2026

Business

Analysts Trim Targets but See Steady Growth Ahead for Abbott Laboratories

Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.

Jan 30, 2026

Business

Edwards Lifesciences Gains Analyst Favor as Renewed Growth Cycle Takes Hold

Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.

Jan 30, 2026

Business

Bitcoin's Stress Test: Price Plunge to $81K Amid $1.7B ETF Exodus Fails to Halt Institutional Buildup

While Bitcoin's sharp correction to nine-month lows triggered massive liquidations and ETF outflows, a deeper look reveals sustained corporate accumulation, state-level adoption proposals, and expanding bank services—painting a picture of a maturing asset class weathering short-term volatility.

Jan 30, 2026

Business

Brazilian Rains Dampen Coffee Market, Sending Prices to Multi-Month Lows

Arabica and robusta coffee futures tumbled sharply on Monday, pressured by forecasts of beneficial rains in Brazil's key growing region and expectations of ample global supplies, with arabica hitting a 5.5-month low.

Jan 30, 2026

Business

OneWater Marine Navigates Flat Waters: Inventory Discipline Drives Margin Growth Amid Stagnant Demand

OneWater Marine's Q4 results reveal a company successfully steering through a challenging market. While revenue growth was minimal, strategic inventory management and a focus on higher-margin segments led to significant profit improvement, offering a blueprint for resilience in the marine industry.

Jan 30, 2026